|Bid||0.00 x 900|
|Ask||0.00 x 1800|
|Day's Range||47.43 - 48.92|
|52 Week Range||30.15 - 64.94|
|Beta (3Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||91.85|
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Wedbush PacGrow Healthcare.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2019, the compensation committee of GBT’s.
Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.And their potential to deliver sky-high returns is especially explosive when they're developing a drug with blockbuster potential.Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They're uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street's pros.Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data shows that all five stocks boast a "Strong Buy" consensus among the Wall Street analysts covering them, based on ratings given during the past three months. SEE ALSO: The 20 Best Small-Cap Dividend Stocks to Buy
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
Global Blood Therapeutics, Inc. (GBT) (GBT), in partnership with sickle cell community-based organizations (CBOs), today announced the launch of Sickle Cell Speaks, a national campaign focused on breaking down stigmas associated with sickle cell disease (SCD). Sickle Cell Speaks is designed to bring together a community of people, from patients to caregivers to friends and relatives, whose lives are affected by SCD. Sickle Cell Speaks aims to inspire hope by showcasing stories of strength and to dispel the misconceptions about SCD.
Currently, there are only two Food & Drug Administration treatments that are approved for sale and use in the U.S.
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriter a 30-day option to purchase up to an additional $30.0 million of additional shares of common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to approximately $30.0 million in shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. GBT intends to use the net proceeds from the offering and its existing capital resources to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, its activities in preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, and future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, and to fund its other research and development activities and for working capital and general corporate purposes. GBT may also use a portion of the net proceeds to in-license, acquire or invest in new business, technology or assets, although it has no material agreements, commitments or understandings in place.
If you're interested in Global Blood Therapeutics, Inc. (NASDAQ:GBT), then you might want to consider its beta (a...
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin greater than 1 g/dL at 24 weeks with voxelotor 1500 mg compared with placebo, with a favorable safety and tolerability profile.
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five nonprofit organizations have been awarded more than.
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor.
The South San Francisco, California-based company said it had a loss of 87 cents per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ...